Percutaneous Laser Ablation in Benign Thyroid Nodules.Long Term Results

Sponsor
Elesta S.R.L. (Industry)
Overall Status
Completed
CT.gov ID
NCT00858104
Collaborator
(none)
200
4
2
53.9
50
0.9

Study Details

Study Description

Brief Summary

Thyroid nodule pathologies occur frequently and represent a clinical issue for the endocrinologists, surgeons, nuclear physicians as well as the general practitioners. The incidence of this pathology has been further highlighted by the introduction of the ultrasound examination into the clinical practice as 20% with impalpable thyroid nodules is now detected through ultrasound. The majority of nodules are benign and characterized by slow growth, and therefore treated with suppressive doses of levothyroxine. Long-term levothyroxine treatment has, however, several well-known side effects and limitations.

During the last years, number of controlled studies have demonstrated that ultrasound guided percutaneous laser treatment (PLA) is able to reach the target lesion within the thyroid with a high level of precision, and to destroy the thyroid tissue in a predictable and repeatable fashion, without side effects.

Aim of the study:
  1. to assess 1-year and 3-year effect of laser ablation therapy on the volume of benign thyroid nodules and on nodule-related symptoms, and to compare these effects with findings in control group without active therapy;

  2. to assess the eventual re-occurence of thyroid lesions (observed after other types of ablation treatment, like percutaneous ethanol injection) during a 3-year follow-up;

  3. to demonstrate reproducibility of results within different environments and under different operators;

  4. to validate eventual presence of major or minor side effects.

To this aim we shall randomized 200 patients either for PLA (100 pts) or standard follow-up. Patients will be recruited, treated and followed in 4 italian centers (Ospedale Regina Apostolorum - Roma, Arcispedale S. Maria Nuova - Reggio Emilia, Ospedale S. Maria della Misericordia - Perugia, Ospedale di Cisanello - Pisa) by physicians with experience in PLA.The scientific coordinator of this multicentre study is dr. Claudio Maurizio Pacella.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Percutaneous Laser Ablation
Phase 4

Study Design

Study Type:
Interventional
Actual Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Multicentric Randomized Controlled Study of Percutaneous Laser Ablation Versus Follow Up in Benign Thyroid Nodules. Long Term Results
Study Start Date :
Nov 1, 2008
Actual Primary Completion Date :
Mar 1, 2010
Actual Study Completion Date :
May 1, 2013

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: 1

Laser thermal ablation

Procedure: Percutaneous Laser Ablation
Single session with standardized approach: Two fibers, up to 2 laser emissions; nodule volume up to 10 ml are treated by 800 Joules /ml and above 10 ml by 600 Joules/ml.The treatment is performed under local anesthesia and with diazepam sedation.
Other Names:
  • Arcispedale S. Maria Nuova is using commercially available system EchoLaser XVG
  • (Integrated Ultrasound-Laser, Elesta, Italy). Other centers are using commercially available
  • systems MyLab70XV (Ultrasound, Esaote, Italy) and Smart1064 BS (Nd:Yag Laser,
  • DEKA, Italy). Disposable Fiber Optic devices : Bare Fiber PLA THY 2111, Bare Fiber PLA S
  • (Asclepion Laser Technologies GmbH, Germany).
  • No Intervention: 2

    Follow-up

    Outcome Measures

    Primary Outcome Measures

    1. Short- (1-year) and long- (3-year) term evolution of the thyroid nodules volume and symptoms after the treatment vs. simple clinical observation.(Strong Endpoint: %nodules with greater than 50% base volume reduction and %patients free of symptoms) [3 years]

    Secondary Outcome Measures

    1. Assessment of short-term and long-term PLA safety, tolerability and reproducibility. [3 years]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • The presence of a single nodule or dominating nodule;

    • A solid or mixed echo-structure with less than 20% fluid volume;

    • A lesion volume between 5 and 18 ml (greatest diameter > 3.0 cm and <= 4 cm);

    • Thyroid hormone and TSH serum levels within the normalcy value;

    • 2 cytologically negative examinations for suspected neoplasia (British Thyroid Association, Second class THY)within the last six months;

    • Calcitonin values within the normalacy value;

    • Anticoagulant treatment suspension and antiaggregation treatment suspended for at least 72 hours.

    Exclusion Criteria:
    • Hyperfunctioning lesion (99mTc scintigraph);

    • Autoimmune thyreopathy or elevation of autoantibodies;

    • Active anticoagulant treatment or antiaggregation treatment.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Ospedale Regina Apostolorum Albano Laziale Roma Italy 00041
    2 Azienda Ospedaliera di Perugia - Osp. S.Maria della Misericordia Perugia Italy 06126
    3 Azienda Ospedaliero-Universitaria di Pisa - Presidio di Cisanello Pisa Italy 56124
    4 Arcispedale S. Maria Nuova Reggio Emilia Italy 42100

    Sponsors and Collaborators

    • Elesta S.R.L.

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Elesta S.R.L.
    ClinicalTrials.gov Identifier:
    NCT00858104
    Other Study ID Numbers:
    • IALT-07
    First Posted:
    Mar 9, 2009
    Last Update Posted:
    May 26, 2014
    Last Verified:
    May 1, 2014
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 26, 2014